1. Home
  2. GVH vs BIVI Comparison

GVH vs BIVI Comparison

Compare GVH & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

N/A

Current Price

$1.29

Market Cap

10.7M

Sector

N/A

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

N/A

Current Price

$1.71

Market Cap

10.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GVH
BIVI
Founded
2016
2013
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
10.3M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
GVH
BIVI
Price
$1.29
$1.71
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$80.00
N/A
AVG Volume (30 Days)
331.6K
4.5M
Earning Date
02-17-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.83
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102,768.97
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.82
52 Week High
$6.46
$3.79

Technical Indicators

Market Signals
Indicator
GVH
BIVI
Relative Strength Index (RSI) 54.76 46.67
Support Level $0.87 $1.74
Resistance Level $1.29 $2.22
Average True Range (ATR) 0.07 0.20
MACD 0.08 -0.03
Stochastic Oscillator 54.81 20.00

Price Performance

Historical Comparison
GVH
BIVI

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: